Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKesson
US Department of Justice
Cerilliant
Farmers Insurance
Chinese Patent Office
Fuji
Deloitte
Moodys

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,169,791

« Back to Dashboard

Which drugs does patent 7,169,791 protect, and when does it expire?

Patent 7,169,791 protects TASIGNA and is included in one NDA.

Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in thirty countries.
Summary for Patent: 7,169,791
Title:Inhibitors of tyrosine kinases
Abstract:The invention relates to compounds of formula ##STR00001## wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
Inventor(s): Breitenstein; Werner (Basel, CH), Furet; Pascal (Thann, FR), Jacob; Sandra (Rantzwiller, FR), Manley; Paul William (Arlesheim, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/520,359
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,169,791

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-003 Mar 22, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y A METHOD FOR THE TREATMENT OF LEUKEMIAS ➤ Try a Free Trial
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,169,791

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0215676.8Jul 05, 2002
United Kingdom0229893.3Dec 20, 2002
United Kingdom0215676.8Jul 5, 2002
PCT Information
PCT FiledJuly 04, 2003PCT Application Number:PCT/EP03/07198
PCT Publication Date:January 15, 2004PCT Publication Number: WO20/04/005281

Non-Orange Book US Patents Family Members for Patent 7,169,791

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,566 Inhibitors of tyrosine kinases ➤ Try a Free Trial
7,956,053 Inhibitors of tyrosine kinases ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,169,791

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 040390 ➤ Try a Free Trial
Austria 414699 ➤ Try a Free Trial
Australia 2003249962 ➤ Try a Free Trial
Brazil 0312464 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
UBS
US Department of Justice
Dow
Merck
Cantor Fitzgerald
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.